Filtered By:
Specialty: General Medicine

This page shows you your search results in order of relevance. This is page number 11.

Order by Relevance | Date

Total 192642 results found since Jan 2013.

A review of peripherally inserted central catheters and various types of vascular access in very small children and pediatric patients and their potential complications
J Med Life. 2021 May-Jun;14(3):298-309. doi: 10.25122/jml-2020-0011.ABSTRACTAccessing the veins for blood delivery, sampling or nutrition is a critical factor in the process of care and management of pediatric patients. In this regard, the peripherally inserted central catheter (PICC) is one of the main alternatives which could be applied effectively as traditional central venous devices in neonates and adults. Due to their essential role in providing safe central venous entry, PICCs could be applied extensively in patients who are critically ill. The main aims of the present study are to review approximately all relevant ...
Source: Journal of Medicine and Life - August 11, 2021 Category: General Medicine Authors: Gholamreza Bahoush Pourya Salajegheh Ali Manafi Anari Alireza Eshghi Behzad Haghighi Aski Source Type: research

Thoracic endovascular repair (TEVAR) versus open surgery for blunt traumatic thoracic aortic injury.
CONCLUSIONS: We found no RCTs conducted to determine whether use of TEVAR for the treatment of BTAI is associated with reduced mortality and morbidity when compared to conventional open repair. Hence, we are unable to provide any evidence to guide the treatment option for this life-threatening condition. To perform a randomised controlled trial to clarify the optimal management of BTAI would be highly challenging due to the natural history of the condition. Despite the lack of RCT evidence, clinicians are moving forward with endovascular treatment of BTAI on the basis of meta-analyses and large clinical series. PMID: ...
Source: Cochrane Database of Systematic Reviews - September 25, 2015 Category: Journals (General) Authors: Pang D, Hildebrand D, Bachoo P Tags: Cochrane Database Syst Rev Source Type: research

Padma 28 for intermittent claudication.
CONCLUSIONS: Some evidence exists from individual trials to suggest that Padma 28 may be effective in increasing walking distances, at least in the short term (four months), in people with IC. Side effects do not appear to be a problem. However, the longer term effects of treatment are unknown and the clinical significance of the improvements in walking distance are questionable. Moreover, the quality of the evidence is limited by the small sample size of the available trials, limited reporting of statistical analyses that compared treatment groups, and relatively high withdrawal rates that were linked to the outcome. That...
Source: Cochrane Database of Systematic Reviews - March 28, 2016 Category: Journals (General) Authors: Stewart M, Morling JR, Maxwell H Tags: Cochrane Database Syst Rev Source Type: research

Phlebotonics for venous insufficiency.
CONCLUSIONS: Moderate-quality evidence shows that phlebotonics may have beneficial effects on oedema and on some signs and symptoms related to CVI such as trophic disorders, cramps, restless legs, swelling and paraesthesia when compared with placebo but can produce more adverse effects. Phlebotonics showed no differences compared with placebo in ulcer healing. Additional high-quality RCTs focused on clinically important outcomes are needed to improve the evidence base. PMID: 27048768 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - April 5, 2016 Category: Journals (General) Authors: Martinez-Zapata MJ, Vernooij RW, Uriona Tuma SM, Stein AT, Moreno RM, Vargas E, Capellà D, Bonfill Cosp X Tags: Cochrane Database Syst Rev Source Type: research

Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
CONCLUSIONS: Anti-VEGF drugs are effective at improving vision in people with DMO with three to four in every 10 people likely to experience an improvement of 3 or more lines VA at one year. There is moderate-certainty evidence that aflibercept confers some advantage over ranibizumab and bevacizumab in people with DMO at one year in visual and anatomic terms. Relative effects among anti-VEGF drugs at two years are less well known, since most studies were short term. Evidence from RCTs may not apply to real-world practice, where people in need of antiangiogenic treatment are often under-treated and under-monitored.We found ...
Source: Cochrane Database of Systematic Reviews - June 22, 2017 Category: General Medicine Authors: Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E Tags: Cochrane Database Syst Rev Source Type: research

Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
CONCLUSIONS: Implications for practice: Intravitreal bevacizumab/ranibizumab, when used as monotherapy, reduces the risk of refractive errors during childhood but does not reduce the risk of retinal detachment or recurrence of ROP in infants with type 1 ROP. While the intervention might reduce the risk of recurrence of ROP in infants with zone I ROP, it can potentially result in higher risk of recurrence requiring retreatment in those with zone II ROP. Intravitreal pegaptanib, when used in conjunction with laser therapy, reduces the risk of retinal detachment as well as the recurrence of ROP in infants with type 1 ROP. How...
Source: Cochrane Database of Systematic Reviews - January 8, 2018 Category: General Medicine Authors: Sankar MJ, Sankar J, Chandra P Tags: Cochrane Database Syst Rev Source Type: research

Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
CONCLUSIONS: Anti-VEGF drugs are effective at improving vision in people with DMO with three to four in every 10 people likely to experience an improvement of 3 or more lines VA at one year. Aflibercept may confer some advantage over ranibizumab and bevacizumab in people with DMO at one year in visual and anatomic terms but it is unclear whether this applies to the long-term. There is a need for more evidence on the long-term (greater than two years) comparative effects of these anti-VEGF agents. Evidence from RCTs may not apply to real-world practice, where people in need of antiangiogenic treatment are often under-treate...
Source: Cochrane Database of Systematic Reviews - October 16, 2018 Category: General Medicine Authors: Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E Tags: Cochrane Database Syst Rev Source Type: research

Traditional Chinese herbal medicine for vascular dementia.
CONCLUSIONS: We found moderate- to very low-quality evidence of benefit and harm of TCHMs for VaD. Methodological inadequacies need to be addressed by better conducted and reported trials. We identified NaoMaiTai, NaoXinTong and TongXinLuo as warranting special research priority. PMID: 30520514 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - December 6, 2018 Category: General Medicine Authors: Chan ES, Bautista DT, Zhu Y, You Y, Long JT, Li W, Chen C Tags: Cochrane Database Syst Rev Source Type: research

Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.
CONCLUSIONS: We found that, at one year, monthly regimens are probably more effective than PRN regimens using seven or eight injections in the first year, but the difference is small and clinically insignificant. Endophthalmitis is probably more common with monthly injections and differences in costs between regimens are higher if aflibercept or ranibizumab are used compared to bevacizumab. This evidence only applies to settings in which regimens are implemented as described in the trials, whereas undertreatment is likely to be common in real-world settings. There are no data from RCTs on long-term effects of different tre...
Source: Cochrane Database of Systematic Reviews - May 4, 2020 Category: General Medicine Authors: Li E, Donati S, Lindsley KB, Krzystolik MG, Virgili G Tags: Cochrane Database Syst Rev Source Type: research

Search strategies (filters) to identify systematic reviews in MEDLINE and Embase
CONCLUSIONS: Studies reporting the development, evaluation, or comparison of search filters to retrieve reports of systematic reviews in MEDLINE showed similar sensitivity and precision, with one filter showing higher levels of specificity. For Embase, filters showed variable sensitivity and precision, with limited information about how the filter was produced, which leaves us uncertain about their performance assessments. Newer filters had limitations in their methods or scope, including very focused subject topics for their gold standards, limiting their applicability across other topics. Our findings highlight that cons...
Source: Cochrane Database of Systematic Reviews - September 8, 2023 Category: General Medicine Authors: Camila Micaela Escobar Liquitay Luis Garegnani Virginia Garrote Ivan Sol à Juan Va Franco Source Type: research